{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:21Z","timestamp":1791357201809,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00228-015-1939-3","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T02:25:19Z","timestamp":1442888719000},"page":"1517-1524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia"],"prefix":"10.1007","volume":"71","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"1939_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/088307389100600102","volume":"6","author":"DL Coulter","year":"1991","unstructured":"Coulter DL (1991) Carnitine, valproate, and toxicity. J Child Neurol 6:7\u201314","journal-title":"J Child Neurol"},{"key":"1939_CR2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s005990050060","volume":"29","author":"A Verrotti","year":"1999","unstructured":"Verrotti A, Greco R, Morgese G, Chiarelli F (1999) Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 29:36\u201340","journal-title":"Int J Clin Lab Res"},{"key":"1939_CR3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.braindev.2010.12.003","volume":"33","author":"Y Nakajima","year":"2011","unstructured":"Nakajima Y, Ito T, Maeda Y, Ichiki S, Kobayashi S. et al. (2011) Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS\/MS. Brain Dev 33: 816\u2013823.","journal-title":"Brain Dev"},{"key":"1939_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yebeh.2007.06.015","volume":"11","author":"AV Chicharro","year":"2007","unstructured":"Chicharro AV, Kanner AM (2007) The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Epilepsy Behav 11:361\u2013366","journal-title":"Epilepsy Behav"},{"key":"1939_CR5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eplepsyres.2012.04.001","volume":"101","author":"Y Yamamoto","year":"2012","unstructured":"Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K. et al. (2012) Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res 101: 202\u2013209.","journal-title":"Epilepsy Res"},{"key":"1939_CR6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/epi.12125","volume":"54","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R. et al. (2013) Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia 54: 983\u2013989.","journal-title":"Epilepsia"},{"key":"1939_CR7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1528-1157.1992.tb01708.x","volume":"33","author":"T Kondo","year":"1992","unstructured":"Kondo T, Ishida M, Kaneko S, Hirano T, Otani K. et al. (1992) Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia? Epilepsia 33: 550\u2013554.","journal-title":"Epilepsia"},{"key":"1939_CR8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","volume":"55","author":"CC Aires","year":"2011","unstructured":"Aires CC, van Cruchten A, Ijlst L, de Almeida IT, Duran M. et al. (2011) New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-Coa. J Hepatol 55: 426\u2013434.","journal-title":"J Hepatol"},{"key":"1939_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0404.1992.tb05085.x","volume":"86","author":"HB Verbiest","year":"1992","unstructured":"Verbiest HB, Straver JS, Colombo JP, van der Vijver JC, van Woerkom TC (1992) Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma. Acta Neurol Scand 86:275\u2013279","journal-title":"Acta Neurol Scand"},{"key":"1939_CR10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","volume":"52","author":"PN Patsalos","year":"2013","unstructured":"Patsalos PN (2013) Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 52:927\u2013966","journal-title":"Clin Pharmacokinet"},{"key":"1939_CR11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","volume":"21","author":"JM Nicholas","year":"2012","unstructured":"Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC (2012) Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the general practice research database. Seizure 21:466\u2013470","journal-title":"Seizure"},{"key":"1939_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.seizure.2013.09.007","volume":"23","author":"WO Pickrell","year":"2014","unstructured":"Pickrell WO, Lacey AS, Thomas RH, Lyons RA, Smith PE. et al. (2014) Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010. Seizure 23: 77\u201380.","journal-title":"Seizure"},{"key":"1939_CR13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pds.1871","volume":"19","author":"SA Hollingworth","year":"2010","unstructured":"Hollingworth SA, Eadie MJ (2010) Antiepileptic drugs in Australia: 2002-2007. Pharmacoepidemiology and Drug Safety. 19:82\u201389","journal-title":"Pharmacoepidemiology and Drug Safety."},{"key":"1939_CR14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2011.05.003","volume":"96","author":"LP Hsieh","year":"2011","unstructured":"Hsieh LP, Huang CY (2011) Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: a population-based national health insurance study. Epilepsy Res 96:81\u201388","journal-title":"Epilepsy Res"},{"key":"1939_CR15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-0404.2006.00639.x","volume":"113","author":"I Tsiropoulos","year":"2007","unstructured":"Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D. et al. (2007) Trends in utilization of antiepileptic drugs in Denmark. Acta Neurologica Scandinavica. 113: 405\u2013411.","journal-title":"Acta Neurologica Scandinavica."},{"key":"1939_CR16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1468-1331.2007.01970.x","volume":"14","author":"R Savica","year":"2007","unstructured":"Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O.et al. (2007) Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. European Journal of Neurology. 14: 1317\u20131321","journal-title":"European Journal of Neurology."},{"key":"1939_CR17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-008-0480-z","volume":"64","author":"NW Vrie-Hoekstra van de","year":"2008","unstructured":"van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT (2008) Antiepileptic drug utilization in children from 1997 to 2005\u2014a study from the Netherlands. European Journal of Clinical Pharmacology. 64:1013\u20131020","journal-title":"European Journal of Clinical Pharmacology."},{"key":"1939_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","volume":"95","author":"CJ Landmark","year":"2011","unstructured":"Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI (2011) Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Research. 95:51\u201359","journal-title":"Epilepsy Research."},{"key":"1939_CR19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-3476(81)80489-1","volume":"99","author":"DL Coulter","year":"1981","unstructured":"Coulter DL, Allen RJ (1981) Hyperammonemia with valproic acid therapy. J Pediatr 99:317\u2013319","journal-title":"J Pediatr"},{"key":"1939_CR20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1468-1331.2006.01268.x","volume":"13","author":"A Oun","year":"2006","unstructured":"Oun A, Haldre S, Magi M (2006) Use of antiepileptic drugs in Estonia: an epidemiologic study of adult epilepsy. Eur J Neurol 13:465\u2013470","journal-title":"Eur J Neurol"},{"key":"1939_CR21","doi-asserted-by":"crossref","unstructured":"Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH. et al. (2014) Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine (Baltimore). 93: e66.","DOI":"10.1097\/MD.0000000000000066"},{"key":"1939_CR22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA. et al. (2008) Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49: 1239\u20131276.","journal-title":"Epilepsia"},{"key":"1939_CR23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","volume":"26","author":"MJ Brodie","year":"1997","unstructured":"Brodie MJ, Yuen AW (1997) Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res 26:423\u2013432","journal-title":"Epilepsy Res"},{"key":"1939_CR24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/epi.12557","volume":"55","author":"MC Groot de","year":"2014","unstructured":"de Groot MC, Schuerch M, de Vries F, Hesse U, Oliva B. et al. (2014) Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison. Epilepsia 55: 666\u2013673.","journal-title":"Epilepsia"},{"key":"1939_CR25","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bcp.12577","volume":"79","author":"D Italiano","year":"2015","unstructured":"Italiano D, Capuano A, Alibrandi A, Ferrara R, Cannata A. et al. (2015) Indications of newer and older antiepileptic drug use: findings from a southern Italian general practice setting from 2005-2011. Br J Clin Pharmacol 79: 1010\u20131019.","journal-title":"Br J Clin Pharmacol"},{"key":"1939_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ. et al. (2013) Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54: 11\u201327.","journal-title":"Epilepsia"},{"key":"1939_CR27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","volume":"53","author":"YC Chuang","year":"2012","unstructured":"Chuang YC, Chuang HY, Lin TK, Chang CC, Lu CH. et al. (2012) Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 53: 120\u2013128.","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"1939_CR28","first-page":"S32","volume":"10","author":"DL Coulter","year":"1995","unstructured":"Coulter DL (1995) Carnitine deficiency in epilepsy: risk factors and treatment. J Child Neurol 10(Suppl 2):S32\u2013S39","journal-title":"J Child Neurol"},{"key":"1939_CR29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1528-1157.1998.tb01315.x","volume":"39","author":"DC Vivo De","year":"1998","unstructured":"De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS. et al. (1998) L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 39: 1216\u20131225.","journal-title":"Epilepsia"},{"key":"1939_CR30","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/j.1528-1167.2011.03279.x","volume":"52","author":"TY Hung","year":"2011","unstructured":"Hung TY, Chen CC, Wang TL, Su CF, Wang RF (2011) Transient hyperammonemia in seizures: a prospective study. Epilepsia 52:2043\u20132049","journal-title":"Epilepsia"},{"key":"1939_CR31","doi-asserted-by":"crossref","unstructured":"Fukuda M, Kawabe M, Takehara M, Iwano S, Kuwabara K. et al. (2015) Carnitine deficiency: risk factors and incidence in children with epilepsy. Brain Dev 37:790\u2013796","DOI":"10.1016\/j.braindev.2014.12.004"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1939-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1939-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1939-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:14Z","timestamp":1558702154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1939-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1939"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1939-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]}}}